Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | VHL | P40337 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12287099 | 0.87 | ADORA2A (0.38) | ADORA2AADORA1KDM4EALDH1A1EGLN1 | |
| SCHEMBL2561403 | 0.81 | LMNA (0.40) | ADORA2AADORA1KDM4EALDH1A1EGLN1 | |
| SCHEMBL2566114 | 0.81 | HPGD (0.41) | ADORA2AALDH1A1CHRM1KMT2AMEN1 | |
| SCHEMBL12286883 | 0.80 | LMNA (0.36) | ADORA2AADORA1KDM4EALDH1A1EGLN1 | |
| SCHEMBL2564666 | 0.78 | MEN1 (0.41) | KDM4EALDH1A1SMN1; SMN2EGLN1KMT2A | |
| SCHEMBL2574725 | 0.76 | ERCC1 (0.42) | EGLN1MAPK1 | |
| SCHEMBL2579592 | 0.70 | MAPT (0.52) | KDM4EALDH1A1SMN1; SMN2EGLN1KMT2A | |
| SCHEMBL2566278 | 0.70 | EGLN1 (0.43) | KDM4EALDH1A1SMN1; SMN2EGLN1MAPK1 | |
| SCHEMBL30525594 | 0.70 | EGLN1 (0.39) | KDM4EALDH1A1SMN1; SMN2TDP1EGLN1 | |
| SCHEMBL29049498 | 0.70 | EGLN1 (0.39) | KDM4EALDH1A1SMN1; SMN2TDP1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560655-B1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME (US) | 2016-08-24 | — | — | EP | claimed |
| US-9006433-B2 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. (US) | 2015-04-14 | — | — | US | claimed |
| US-20130018053-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME LLC | 2013-01-17 | — | — | US | claimed |
| WO-2011130908-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP. (US) | 2011-10-27 | — | — | WO | claimed |
| EP-2560655-B1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME (US) | 2016-08-24 | — | — | EP | disclosed |
| EP-2560655-B1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME (US) | 2016-08-24 | — | — | EP | disclosed |
| US-9006433-B2 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006433-B2 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. (US) | 2015-04-14 | — | — | US | disclosed |
| EP-2560655-A1 | SUBSTITUTED PYRIMIDINES | Merck Sharp & Dohme Corp. (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20130018053-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME LLC | 2013-01-17 | — | — | US | disclosed |
| US-20130018053-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME LLC | 2013-01-17 | — | — | US | disclosed |
| WO-2011130908-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133444-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018053-A1 | SUBSTITUTED PYRIMIDINES | HIF1AN, HIF1A, EGLN3 | ADORA2A 874/4885ADORA1 815/4885KDM4E 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.